CONTRIBUTED POSTER PRESENTATIONS SESSION I

POSTER SESSION I - MONDAY, MAY 22, 2006

   

Neurological Disorders

   
PNL1 CLINICAL EFFECTIVENESS AND HEALTH OUTCOMES OF DISEASE MODIFYING TREATMENT (DMT) THAT DELAYS DISABILITY PROGRESSION IN RELAPSING/REMITTING-ONSET MULTIPLE SCLEROSIS: NOVA SCOTIA ‘REAL WORLD' EVIDENCE
  Brown MG1, Kirby S1, Fisk JD1, Sketris IS2, Hoch J3, Bhan V1, Murray TJ1, Skedgel C1, MacKinnon-Cameron D1, Stadnyk K1
  1Capital Health Nova Scotia, Halifax, NS, Canada, 2Dalhousie University, Halifax, NS, Canada, 3University of Toronto, Toronto, ON, Canada
   
PNL2 RESTLESS LEGS SYNDROME: IDENTIFICATION OF TREATED PATIENTS IN A LARGE CLAIMS DATABASE
  Montejano LB1, Long SR2, Baser O3, Lobo F4, Curtice TG5
  1Thomson Medstat, Washington, DC, USA, 2Thomson Medstat, Hampden, ME, USA, 3Thomson Medstat, Ann Arbor, MI, USA, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 5Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA
   
PNL3 HOSPITAL LENGTH OF STAY ASSOCIATED WITH ANTICONVULSANT UTILIZATION BY PATIENTS WITH SEIZURE DISORDERS IN THE U.S.
  Blanchette CM, Stemkowski S, Craver C, Wang PF, Saunders W
  Premier, Inc, Charlotte, NC, USA
   
PNL4 WITHDRAWN
   
PNL5 ASSESSING ABSOLUTE REDUCTIONS IN CLINICAL EFFECT: A MODEL FOR COMPARING THE COST-EFFECTIVENESS OF DISEASE MODIFYING DRUGS (DMDS) UTILIZED IN THE TREATMENT OF MULTIPLE SCLEROSIS (MS)
  Goldberg LD1, Akhras KS2, AL-Sabbagh A2, Hall B2
  1Goldberg, MD & Associates, Battle Ground, WA, USA, 2Serono, Rockland, MA, USA
   
PNL6 EXAMINATION OF THE COST-EFFECTIVENESS OF DOPAMINE AGONISTS FOR THE TREATMENT OF RESTLESS LEGS SYNDROME
  Beard AJ
  University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
   
PNL7 COST-EFFICACY ANALYSIS OF MULTIPLE SCLEROSIS THERAPIES: ASSESSING THE IMPACT OF NEUTRALIZING ANTIBODIES
  Munschauer F1, Baker T2, Dunn J3, Cook R4, Likosky W5, Stefoski D6
  1State University of New York at Buffalo, Buffalo, NY, USA, 2The Zitter Group, San Francisco, CA, USA, 3IHC Health Plans, Salt Lake City, UT, USA, 4Blue Care Network of Michigan, Grand Rapids, MI, USA, 5Swedish Medical Center, Seattle, WA, USA, 6Rush University Medical Center, Chicago, IL, USA
   
PNL8 ASSESSING THE COST-EFFECTIVENESS OF IMMUNOMODULATORY THERAPIES FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS BASED ON LONG-TERM DATA
  Bell CF1, Graham JB1, Earnshaw SR1, Oleen-Burkey M2, Castelli-Haley J2, Johnson KP3
  1RTI Health Solutions, Research Triangle Park, NC, USA, 2Teva Neuroscience, Inc, Kansas City, MO, USA, 3University of Maryland, Baltimore, MD, USA
   
PNL9 COST-EFFECTIVENESS OF TOPIRAMATE FOR MIGRAINE PREVENTION: A MANAGED CARE PERSPECTIVE
  Brown J1, Rupnow M2, Neumann PJ3, Friedman M1, Menzin J1
  1Boston Health Economics, Inc, Waltham, MA, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 3Tufts University School of Medicine, Boston, MA, USA
   
PNL10 COST-EFFECTIVENESS OF MS DISEASE MODIFYING AGENTS: A MARKOV AND VALUE OF INFORMATION ANALYSIS
  Lundy J, Coons SJ
  University of Arizona, Tucson, AZ, USA
   
PNL11 COMPARING APPLES WITH WHAT: DIFFERENT INPUTS AND ASSUMPTIONS PRODUCE DIFFERENT CONCLUSIONS IN MS ECONOMIC MODELS
  Noyes K1, Daumer M2, Dick A3, Dorsey R1, Holloway R1, Li C1, McCabe C4, Miller D5, Schwid S1, Shih HC1
  1University of Rochester School of Medicine, Rochester, NY, USA, 2Sylvia Lawry Centre for Multiple Sclerosis Research, Munich, Germany, 3The RAND Corporation, Pittsburgh, PA, USA, 4University of Sheffield, Sheffield, England, 5Cleveland Clinic Foundation, Cleveland, OH, USA
   
PNL12 COST-EFFECTIVENESS OF ELETRIPTAN VERSUS SUMATRIPTAN: RESULTS FROM A RANDOMIZED, CONTROLLED TRIAL
  Weis K1, Perfetto E2, Mullins CD3, Healey P1, Subedi P3, Meng F3
  1Pfizer Pharmaceutical Group, New York, NY, USA, 2WEINBERG Group, Inc, Washington, DC, USA, 3University of Maryland School of Pharmacy, Baltimore, MD, USA
   
PNL13 ′WINNERS′ AND ′LOSERS′: PATTERNS IN ECONOMIC EVALUATIONS OF ANTI-EPILEPTIC DRUGS
  Mladsi D1, Barrett A1, Lindley N2
  1RTI Health Solutions, RTP, NC, USA, 2Abbott Laboratories, Abbott Park, IL, USA
   
PNL14 COST-EFFECTIVENESS OF PREGABALIN AS ADJUNCT TO STANDARD THERAPY IN PATIENTS WITH REFRACTORY PARTIAL EPILEPSY
  Vera-Llonch M1, Brandenburg NA2, Delea T1, Wang ST3, Oster G1
  1PAI, Brookline, MA, USA, 2Pfizer Global Pharmaceuticals, Inc, New York City, NY, USA, 3Harvard School of Public Health, Boston, MA, USA
   
PNL15 COST-OF-ILLNESS FOR ADULTS WITH PARTIAL EPILEPSY IN SWEDEN
  Mork AC1, Oscarius K1, Pettersson C1, Forsgren L2, Edström M2, Lundgren A3, Håkansson M3, Källen K3
  1Pfizer Sweden, Sollentuna, Stockholm, Sweden, 2Umea University Hospital, Umea, Sweden, 3Lund University Hospital, Lund, Sweden
   
PNL16 ECONOMIC BURDEN OF PAIN DUE TO MULTIPLE SCLEROSIS IN CANADA
  Piwko C1, Desjardins O1, Bereza B1, Jaszewski B2, Iskedjian M1, Einarson TR3
  1PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, 2Bayer Healthcare, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada
   
PNL17 ECONOMIC COSTS OF CHRONIC PRIMARY INSOMNIA IN THE UNITED STATES
  Thompson D1, Chhabra A1, Treglia M2, Healey P3, O'Sullivan AK1, McGarry L1, Weinstein MC4, Winkelman JW5
  1INNOVUS Research Inc, Medford, MA, USA, 2Pfizer Inc, Groton, CT, USA, 3Pfizer Inc, New York, NY, USA, 4INNOVUS Research Inc., Harvard School of Public Health, Harvard Medical School, Boston, MA, USA, 5Sleep Health Center, Brigham and Women's Hospital, Harvard Medical School, Newton, MA, USA
   
PNL18 DIRECT COST BURDEN OF MIGRAINE AMONG MEMBERS OF US EMPLOYER GROUPS
  Hawkins K1, Rupnow M2, Wang S3
  1Thomson-Medstat, Ann Arbor, MI, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 3Thomson-Medstat, Cambridge, MA, USA
   
PNL19 ECONOMIC BURDEN OF RESTLESS LEGS SYNDROME IN A PRIVATELY-INSURED POPULATION
  Curtice TG1, Long SR2, Baser O3, Montejano LB4, Lobo F5
  1Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA, 2Thomson Medstat, Hampden, ME, USA, 3Thomson Medstat, Ann Arbor, MI, USA, 4Thomson Medstat, Washington, DC, USA, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
   
PNL20 HEALTH CARE ECONOMIC BENCHMARKS FOR MULTIPLE SCLEROSIS IN A COMMERCIAL MANAGED CARE ENVIRONMENT
  Prescott J
  The MCM Group, Marlton, NJ, USA
   
PNL21 PATTERNS OF TOPIRAMATE UTILIZATION AMONG MEDICAID PATIENTS: DIAGNOSIS, COMORBIDITIES AND REAL-WORLD DOSING
  Poston S1, Rupnow M2, Dickson M3, Johnsrud M4, Gdovin JM5, Bramley T6, Armstrong RB7
  1Thomas Jefferson University, Philadelphia, PA, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 3University of South Carolina, College of Pharmacy, Columbia, SC, USA, 4University of Texas-Austin, Austin, TX, USA, 5Applied Health Outcomes, Palm Harbor, FL, USA, 6Applied Health Outcomes, Salt Lake City, UT, USA, 7Ortho-McNeil Neurologics, Inc, Titusville, NJ, USA
   
PNL22 ESTIMATING THE COST OF NURSING HOME CARE FOR PATIENTS WITH PARKINSON'S DISEASE USING RETROSPECTIVE DATABASE ANALYSIS
  Anderson K1, Faris R2
  1University of Tennessee, Memphis, TN, USA, 2Methodist Hospital, Memphis, TN, USA
   
PNL23 CONTROLLING SELECTION BIAS ON CONTINUOUS VARIABLES
  Baser O
  Thomson Medstat, Ann Arbor, MI, USA
   
PNL24 THE ESTIMATION POWER OF ALTERNATIVE COMORBIDITY INDEXES
  Baser O1, Stephenson J2
  1Thomson-Medstat, Ann Arbor, MI, USA, 2Thomson Medstat, Philadelphia, PA, USA
   
PNL25 FAILURE OF REGRESSION ADJUSTMENT AGAINST PROPENSITY SCORE MATCHING
  Baser O
  Thomson-Medstat, Ann Arbor, MI, USA
   
PNL26 EXTENDING MATCHING ESTIMATORS OF CAUSAL EFFECTS TO CONSIDER UNOBSERVED VARIABLE BIAS: AN APPLICATION OF SENSITIVITY ANALYSIS
  Devine JW, Hadsall RS, Farley JF
  University of Minnesota, Minneapolis, MN, USA
   
PNL27 THE EFFECT OF ADHERENCE TO ALZHEIMER'S DISEASE TREATMENT ON HEALTH CARE COSTS IN MANAGED CARE
  Harada ASM, Vanderplas AM
  Prescription Solutions, Irvine, CA, USA
   
PNL28 STUDYING DISCONTINUATION, SWITCHING, AND AUGMENTATION USING COMPETING RISK METHODS
  Gause D, Arcona S
  Novartis Pharmaceuticals, East Hanover, NJ, USA
   
PNL29 A REVIEW OF THE VALIDITY AND RELIABILITY OF THE PARKINSON'S DISEASE QUESTIONNAIRE (PDQ-39)
  Stafkey-Mailey DR1, Gwadry-Sridhar F2
  1University of Southern California, Los Angeles, CA, USA, 2University of Western Ontario, and London Health Sciences Centre, London, ON, Canada
   
PNL30 COMPARISON OF HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRES IN MULTIPLE SCLEROSIS: A REVIEW
  Pawar VS, Miller LA
  West Virginia University, Morgantown, WV, USA
   
PNL31 HEALTHCARE UTILIZATION AND PATIENT SATISFACTION WITH TRIPTAN TREATMENT IN MIGRAINEURS
  Ambegaonkar A1, Livengood K2, Holdsworth K3, Fixler K3, Tiseo P3
  1Pfizer Inc, New York, NY, USA, 2Pfizer, Inc, Yorba Linda, CA, USA, 3Pfizer, Inc, New York, NY, USA
   
PNL32 EVALUATION OF THE IMPACT OF AN EMPLOYEE WORKSITE DISEASE MANAGEMENT PROGRAM FOR MIGRAINEURS ON WORK PRODUCTIVITY
  Borok GM1, Ershoff DH2, Maurer R3
  1AstraZeneca, Encino, CA, USA, 2AstraZeneca, Tarzana, CA, USA, 3St. Jude Heritage Medical Group, La Mirada, CA, USA

Poster Session II
11th Annual Meeting Main Page
 

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2010 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.